15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Capricor Therapeutics Inc, 5 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $2.00 to $63.00 (about 31.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $38.57 sits 325% above the current $9.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-1.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy563%
Hold338%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Capricor Therapeutics Inc.
As of Sep, 5 of 8 firms rate CAPR a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CAPR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.73 – $3.01 · 8 analysts · -85% YoY
Next period, 8 analysts expect Capricor Therapeutics Inc to earn $-0.10 a share (range $-0.73 – $3.01), versus $-0.62 a year earlier. Full-year consensus is $-2.27, growing to $-1.48 the year after.
REVENUE · NEXT QUARTER
$27.9M
Range $0 – $211.7M · 8 analysts
Revenue is expected to reach $27.9M (range $0 – $211.7M). Full-year consensus is $16.4M, rising to $56.5M next year.
Top analysts covering Capricor Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CAPR.
#1
Kristen Kluska
Cantor Fitzgerald · Rank #169
Buy
$28.00+208.7% to target
Overall win rate
38%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Hold
No targeton CAPR
Overall win rate
34%
+ Follow
#3
Leland Gershell
Oppenheimer · Rank #307
Hold
No targeton CAPR
Overall win rate
37%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #337
Hold
$2.00-77.9% to target
Overall win rate
29%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #428
Hold
No targeton CAPR
Overall win rate
32%
+ Follow
CAPR stock forecast FAQ
What is CAPR's average 12-month price target?+
The 6 analysts with a live target average $38.57 for Capricor Therapeutics Inc over the next 12 months, ranging from a $63.00 high to a $2.00 low.
Is CAPR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 5 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CAPR?+
The Street-high target is $63.00 (B. Riley Securities), and the Street-low is $2.00 (Piper Sandler). The average of all 6 active targets is $38.57.
How many Wall Street analysts cover CAPR?+
8 analysts have an active rating on Capricor Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CAPR?+
Among analysts who currently cover CAPR, Kristen Kluska of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #169). Their current call is Buy with a $28.00 target.
What is Capricor Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.73 – $3.01) across 8 analysts. Full-year EPS is projected at $-2.27, rising to $-1.48 the following year.
How much revenue is Capricor Therapeutics Inc expected to report next quarter?+
Consensus revenue is $27.9M (range $0 – $211.7M). Full-year revenue is projected at $16.4M, growing to $56.5M next year.
Have analysts been upgrading or downgrading CAPR lately?+
As of Sep, 5 of 8 firms rate CAPR a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CAPR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
